

# China COVID-19 policy

**Free to View**

## 20 measures for better calibration

Economics - China

- ◆ China's National Health Commission announced a calibration of measures to combat COVID-19 on the ground amid the worst outbreak since the spring
- ◆ Quarantine time is cut for close contacts of COVID cases to 5 days at a central facility plus 3 days at home ('5+3'), same for inbound travellers; no further identification of 'secondary close contacts'
- ◆ Mass PCR testing removed in most areas, "excessive" containment measures by local government halted (such as school and work suspension, and patient rejection), and circuit breaker bans for international flights scrapped

**Jing Liu**  
Chief Economist Greater China  
The Hongkong and Shanghai  
Banking Corporation Limited

**Erin Xin**  
Economist, Greater China  
The Hongkong and Shanghai  
Banking Corporation Limited

## Facts

The Comprehensive Team for Joint Prevention and Control Mechanism for Covid-19 posted "New measures to further optimize China's pandemic control" ("关于进一步优化新冠肺炎疫情防控措施、科学精准做好防控工作的通知") on the National Health Commission (NHC) website today.

The announcement came after the Standing Committee of the Politburo met for the first time yesterday, where it discussed it would research and deploy 20 measures for further optimizing epidemic prevention and control work. Most notably, the new measures (Table 1) will reduce quarantine time for close contacts to '5+3' days from '7+3' days previously. Similar rules will apply for inbound travellers.

In addition, the circuit breaker measures for inbound flights will be cancelled and the pre-departure Covid-19 tests requirement for inbound travellers will be lowered as well.

While the zero-COVID policy still applies, the central government pledged to avoid the 'one-size-for-all' approach or the excessive policy steps that have been taken on the local level. The statement further clarifies that lockdowns must be ended in a timely manner once the low-risk criteria are met.

In terms of vaccines, there will be a promotion drive to accelerate coverage of booster shots of Covid-19 vaccines, particularly for the elderly. Meanwhile, "excessive" campus closures and control measures shall be avoided.

The announcement came at a time when the national daily infections broke 10,000 for the first time since April. Guangdong, China's largest province in economic terms is now the epicentre with daily new cases exceeding 2,000 since 6 November. There hasn't been a full-scale lockdown of Guangzhou city so far, an approach seemingly in line with the calibration of COVID measures.

Link to statement (Chinese): [http://www.gov.cn/xinwen/2022-11/11/content\\_5726144.htm](http://www.gov.cn/xinwen/2022-11/11/content_5726144.htm)

*This is a Free to View version of a report with the same title published on 11-Nov-22. Please contact your HSBC representative or email [AskResearch@hsbc.com](mailto:AskResearch@hsbc.com) for more information.*

**Disclosures & Disclaimer:** This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

**Issuer of report:** The Hongkong and Shanghai Banking Corporation Limited

**View HSBC Global Research at:** <https://www.research.hsbc.com>

**Table 1. Key measures and changes in the "Twenty Measures to Further Optimize Prevention and Control Work"**

Topic	Key measures and changes
Close contacts and quarantine times	For close contacts, the management measures of "7-day centralized quarantine + 3-day at home health monitoring" are <b>adjusted to "5-day centralized quarantine + 3-day home quarantine"</b> . <b>This is also applied for inbound travellers.</b> Timely and accurately determine close contacts, and <b>no longer determine secondary close contacts</b>
Other quarantine	The "7-day centralized quarantine" for <b>those travelling from high-risk areas has been adjusted to "7-day home quarantine"</b> . For employees in <b>high-risk areas who have completed closed-loop operations will only need to undergo "5-day home health monitoring"</b> from the previous "7-day centralized quarantine or 7-day home quarantine"
Risk area delineation	<b>Risk area delineations reduced to "high and low"</b> from the previous "high, medium and low" to minimize the number of control personnel. High-risk areas are generally demarcated by units and buildings, and may not be expanded arbitrarily.
Nucleic acid testing	<b>Nucleic acid testing is not to be carried out for all persons in an administrative region arbitrarily</b> , but only when the source of infection and transmission chain are unclear, and the community transmission time is relatively long. Remove twice or thrice daily nucleic acid testing.
Inbound flight	<b>The circuit breaker mechanism for inbound flights will be cancelled</b> , and the requirement of two negative nucleic acid test certificates within 48 hours before boarding will be adjusted to <b>one negative nucleic acid test certificate within 48 hours before boarding</b> .
Inbound personnel	Positive case judgment standard for inbound personnel is a Ct value <35 in nucleic acid detection
Epidemic prevention and control	<b>Rectify the "one-size-fits-all", "layer-by-layer" problem</b> . It is strictly forbidden to close schools and classes, stop work and production, block traffic without approval, arbitrarily adopt "static" management, arbitrarily block and control, not unblock for a long time, and stop clinics at will.
Enterprise production	Make every effort to ensure the smooth flow of logistics, and do not arbitrarily require key enterprises that are related to the overall situation of the industrial chain and related to people's livelihood to suspend production and production, and implement the "white list" system.
Vaccine development	Accelerate the coverage rate of vaccine booster immunization, especially for the elderly. Accelerate the development of monovalent or multivalent (mRNA) vaccines with broad-spectrum protection, and promote approval in accordance with laws and regulations.

Source: National Health Commission; Key changes are **bolded**

## Implications

The latest policy announcements suggest that the central government is paving the way for a gradual reopening, which aligns with our expectation that the government will re-focus on economic growth and aim for a better balance going into 2023. Relaxation of COVID-19 measures, together with a further step-up in macro policy support, may help with the domestic demand recovery.

Having said that, the reopening process will be gradual and delicate. The preparation involves public education, a vaccination campaign especially among the elderly, stockpiling medicine and medical equipment to treat COVID etc., which could take months. President Xi also stressed in yesterday's Politburo meeting that the pandemic situation is likely to further escalate during the winter time. Our base case remains that China will see a gradual, further relaxation of COVID-19 policies in 1H next year, helping to stabilize the housing market and support the consumption recovery.

Today's relaxation should help to minimize the direct drag on economic activity and help to lift sentiment. In particular, services and offline retail should see improvement, as well as broader activity as expectations for further easing of restrictions gains traction.

Additionally, the Deputy Governor of mainland China's NHC praised Hong Kong for its management of the COVID-19 situation in a scientific and targeted approach in the Asia Summit on Global Health yesterday (Caixin, 11 November). Hong Kong has taken a gradual approach towards relaxing COVID-19 restrictions, with eventual relaxation of mandatory quarantine for inbound travellers (though 3 days of at-home monitoring remain) over the course of several months.

Easing measures are not limited to the COVID-19 front. The National Association of Financial Market Institutional Investors (NAFMII) recently announced further support for private bond issuance, including property developers, with the PBoC offering RMB250bn in related re-lending facilities. Today, the Chinese property developer, Longfor, received approval from NAFMII to issue RMB20bn via "shelf registration", meaning it could be offered in batches. We expect the economic recovery will further solidify on the back of the gradual relaxation of COVID-19 measures and a stabilizing property market which should help growth to reach over 5% in 2023.

# Disclosure appendix

The following analyst(s), who is(are) primarily responsible for this document, certifies(y) that the opinion(s), views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Jing Liu and Erin Xin

This document has been issued by the Research Department of HSBC.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at [www.hsbcnet.com/research](http://www.hsbcnet.com/research).

## Additional disclosures

- 1 This report is dated as at 11 November 2022.
- 2 All market data included in this report are dated as at close 11 November 2022, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

# Disclaimer

Issuer of report  
The Hongkong and Shanghai Banking Corporation  
Limited

This document has been issued by The Hongkong and Shanghai Banking Corporation Limited, which has based this document on information obtained from sources it believes to be reliable but which it has not independently verified. Neither The Hongkong and Shanghai Banking Corporation Limited nor any member of its group companies ("HSBC") make any guarantee, representation or warranty nor accept any responsibility or liability as to the accuracy or completeness of this document and is not responsible for errors of transmission of factual or analytical data, nor is HSBC liable for damages arising out of any person's reliance on this information. The information and opinions contained within the report are based upon publicly available information at the time of publication, represent the present judgment of HSBC and are subject to change without notice.

This document is not and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment or other investment products mentioned in it and/or to participate in any trading strategy. It does not constitute a prospectus or other offering document. Information in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on it, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

The decision and responsibility on whether or not to purchase, subscribe or sell (as applicable) must be taken by the investor. In no event will any member of the HSBC group be liable to the recipient for any direct or indirect or any other damages of any kind arising from or in connection with reliance on any information and materials herein.

Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed. Some of the statements contained in this document may be considered forward looking statements which provide current expectations or forecasts of future events. Such forward looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors.

This document is for information purposes only and may not be redistributed or passed on, directly or indirectly, to any other person, in whole or in part, for any purpose. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report, you agree to be bound by the foregoing instructions. If this report is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. The document is intended to be distributed in its entirety. Unless governing law permits otherwise, you must contact a HSBC Group member in your home jurisdiction if you wish to use HSBC Group services in effecting a transaction in any investment mentioned in this document.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document.

HSBC and/or its officers, directors and employees may have positions in any securities in companies mentioned in this document. HSBC may act as market maker or may have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell or buy securities and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented on the supervisory board or any other committee of those companies.

From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority.

© Copyright 2022, The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of insert issuing entity name. MCI (P) 037/01/2022, MCI (P) 017/10/2021